PDS Biotechnology
PDSB | NASDAQ
$0.92
+$0.05 (+5.43%)
At close: Nov 16, 2026, 4:00 PM ET
$0.91
-$0.01 (-0.67%)
After-hours:
Nov 16, 2026, 7:48 PM ET
+5.43%
(1D)No price chart data available for 1D timeframe.
Rating
32.2
Fundamentals Weak
Market Sentiment Neutral
Moat None
Sector Rank #742/1021 (Top 73%)
Key Statistics
Market Data
Market Cap $66.18M
1D Range
0.81 0.97
52W Range
0.20 1.60
Valuation (TTM)
PE -1.64
PB -18.49
EV/EBITDA -2.58
Valuation (NTM)
Forward PE N/A
Forward PEG 0.03
Price Target $4.00
Cash Flow
FCF Yield -25.4%
SBC Adj. FCF Yield -29.0%
SBC Impact -14.3%
Margins
Gross Margin 0.0%
Operating Margin 0.0%
FCF Margin N/A
Growth (CAGR)
Revenue 3Y | 5Y N/A |
N/A
Dil EPS 3Y | 5Y 35.3% |
17.2%
FCF 3Y | 5Y 31.0% |
2.6%
Returns
ROA -366.6%
ROE -679.0%
ROIC -3264.1%
Financial Health
Net Cash
$1.27M
Current Ratio 0.57
Interest Coverage -3.52
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV1...
Sector Healthcare
Industry Biotechnology
Employees 21
IPO Date Sep 30, 2015
Website www.pdsbiotech.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$4.00
Upside
+334.78%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PDSB